Bellevue Group AG Buys Shares of 15,700 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Bellevue Group AG purchased a new position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 15,700 shares of the company’s stock, valued at approximately $500,000.

A number of other large investors also recently modified their holdings of FDMT. Bfsg LLC bought a new position in 4D Molecular Therapeutics during the 4th quarter valued at $30,000. Allspring Global Investments Holdings LLC grew its holdings in 4D Molecular Therapeutics by 702.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock worth $110,000 after acquiring an additional 3,026 shares during the period. China Universal Asset Management Co. Ltd. raised its position in 4D Molecular Therapeutics by 359.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,951 shares of the company’s stock worth $100,000 after acquiring an additional 3,873 shares in the last quarter. Daiwa Securities Group Inc. lifted its holdings in 4D Molecular Therapeutics by 23.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 5,872 shares of the company’s stock valued at $119,000 after acquiring an additional 1,110 shares during the last quarter. Finally, Entropy Technologies LP bought a new position in shares of 4D Molecular Therapeutics during the 1st quarter valued at about $239,000. 99.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently commented on FDMT. Chardan Capital reiterated a “buy” rating and issued a $38.00 target price on shares of 4D Molecular Therapeutics in a report on Wednesday, July 17th. Jefferies Financial Group lifted their target price on 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a “buy” rating in a report on Monday, April 1st. BMO Capital Markets reduced their target price on 4D Molecular Therapeutics from $63.00 to $40.00 and set an “outperform” rating for the company in a report on Thursday, July 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $40.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, July 22nd. Finally, Barclays began coverage on 4D Molecular Therapeutics in a report on Monday, April 15th. They set an “overweight” rating on the stock. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat, 4D Molecular Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $43.63.

4D Molecular Therapeutics Stock Down 7.5 %

Shares of FDMT traded down $1.37 during trading hours on Monday, reaching $16.98. The company’s stock had a trading volume of 230,094 shares, compared to its average volume of 955,392. The firm has a market cap of $877.87 million, a price-to-earnings ratio of -7.11 and a beta of 2.84. The company has a 50 day moving average of $22.60 and a two-hundred day moving average of $24.92. 4D Molecular Therapeutics, Inc. has a 1-year low of $9.44 and a 1-year high of $36.25.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Thursday, May 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.07. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $1.44 million. As a group, analysts forecast that 4D Molecular Therapeutics, Inc. will post -2.98 EPS for the current fiscal year.

Insider Transactions at 4D Molecular Therapeutics

In related news, insider Scott Bizily sold 1,750 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $25.45, for a total value of $44,537.50. Following the transaction, the insider now owns 1,737 shares in the company, valued at $44,206.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other 4D Molecular Therapeutics news, insider Scott Bizily sold 1,750 shares of the stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $25.45, for a total transaction of $44,537.50. Following the transaction, the insider now directly owns 1,737 shares of the company’s stock, valued at $44,206.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO David Kirn sold 12,930 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $23.10, for a total value of $298,683.00. Following the completion of the sale, the chief executive officer now directly owns 1,059,153 shares of the company’s stock, valued at approximately $24,466,434.30. The disclosure for this sale can be found here. Insiders sold 35,597 shares of company stock valued at $821,939 in the last three months. Corporate insiders own 7.30% of the company’s stock.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.